The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-10-07

AUTHORS

Nanae Horisawa, Yayoi Adachi, Daiki Takatsuka, Kazuki Nozawa, Yuka Endo, Yuri Ozaki, Kayoko Sugino, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Hiroji Iwata

ABSTRACT

PurposeThe DESTINY-Breast04 clinical trial is currently investigating whether trastuzumab deruxtecan (T-DXd) is effective in HER2-low as well as HER2-positive breast cancer. This highlights the interest in treatment strategies for patients with HER2-low breast cancer. The current study was therefore designed to determine the frequency of HER2-low among all breast cancers, and to compare the prognosis of HER2-low patients with that of HER2-negative patients.MethodsWe retrospectively reviewed the biological data from 4,918 of 4,977 primary breast cancer patients who attended our institute. We quantified the overall frequency of breast cancer patients with a new HER2-low subtype that was defined by an immunohistochemistry score of IHC1 + or IHC2 + /ISH−. We then compared the clinical characteristics and prognosis of HER2-low patients with that of patients who did not have HER2 amplification (HER2-0).ResultsLow HER2 expression was found in 3169 (64.4%) patients; 2860 (58.1%) were HR-positive and 309 (6.3%) were HR-negative. Among HER2-0 patients, 681 (13.9%) were HR-positive and 157 (3.2%) were HR-negative. The HER2-0 group tended to have more poor prognostic factors than the HER2-low group, irrespective of HR status. There were no statistically significant differences between the prognosis of HER2-low and HER2-0 patients, regardless of HR status. However, patients in the HER2-low group tended to have better prognosis than those in the HER2-0 group.ConclusionHER2-low patients did not have a significantly different prognosis than HER2-0 patients, regardless of HR status. However, we should consider tailoring therapies for patients with HRE2-low early breast cancer according to their HR status. More... »

PAGES

234-241

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-021-01303-3

DOI

http://dx.doi.org/10.1007/s12282-021-01303-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1141720951

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34622383


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horisawa", 
        "givenName": "Nanae", 
        "id": "sg:person.012576646500.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012576646500.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adachi", 
        "givenName": "Yayoi", 
        "id": "sg:person.0757400343.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757400343.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takatsuka", 
        "givenName": "Daiki", 
        "id": "sg:person.012735232557.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012735232557.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Clinical Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nozawa", 
        "givenName": "Kazuki", 
        "id": "sg:person.011661742244.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011661742244.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Endo", 
        "givenName": "Yuka", 
        "id": "sg:person.014731505151.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014731505151.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozaki", 
        "givenName": "Yuri", 
        "id": "sg:person.012167214007.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012167214007.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sugino", 
        "givenName": "Kayoko", 
        "id": "sg:person.015174445210.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015174445210.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kataoka", 
        "givenName": "Ayumi", 
        "id": "sg:person.011635171771.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011635171771.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kotani", 
        "givenName": "Haruru", 
        "id": "sg:person.0643151743.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643151743.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshimura", 
        "givenName": "Akiyo", 
        "id": "sg:person.0711265143.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711265143.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Masaya", 
        "id": "sg:person.01030570677.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030570677.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sawaki", 
        "givenName": "Masataka", 
        "id": "sg:person.01332406364.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332406364.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwata", 
        "givenName": "Hiroji", 
        "id": "sg:person.013142720612.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013142720612.73"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10549-019-05148-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111893543", 
          "https://doi.org/10.1007/s10549-019-05148-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41523-020-00208-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134289053", 
          "https://doi.org/10.1038/s41523-020-00208-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-016-1940-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005592412", 
          "https://doi.org/10.1007/s00428-016-1940-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-015-3407-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009019478", 
          "https://doi.org/10.1007/s10549-015-3407-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-10-07", 
    "datePublishedReg": "2021-10-07", 
    "description": "PurposeThe DESTINY-Breast04 clinical trial is currently investigating whether trastuzumab deruxtecan (T-DXd) is effective in HER2-low as well as HER2-positive breast cancer. This highlights the interest in treatment strategies for patients with HER2-low breast cancer. The current study was therefore designed to determine the frequency of HER2-low among all breast cancers, and to compare the prognosis of HER2-low patients with that of HER2-negative patients.MethodsWe retrospectively reviewed the biological data from 4,918 of 4,977 primary breast cancer patients who attended our institute. We quantified the overall frequency of breast cancer patients with a new HER2-low subtype that was defined by an immunohistochemistry score of IHC1\u2009+\u2009or IHC2\u2009+\u2009/ISH\u2212. We then compared the clinical characteristics and prognosis of HER2-low patients with that of patients who did not have HER2 amplification (HER2-0).ResultsLow HER2 expression was found in 3169 (64.4%) patients; 2860 (58.1%) were HR-positive and 309 (6.3%) were HR-negative. Among HER2-0 patients, 681 (13.9%) were HR-positive and 157 (3.2%) were HR-negative. The HER2-0 group tended to have more poor prognostic factors than the HER2-low group, irrespective of HR status. There were no statistically significant differences between the prognosis of HER2-low and HER2-0 patients, regardless of HR status. However, patients in the HER2-low group tended to have better prognosis than those in the HER2-0 group.ConclusionHER2-low patients did not have a significantly different prognosis than HER2-0 patients, regardless of HR status. However, we should consider tailoring therapies for patients with HRE2-low early breast cancer according to their HR status.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12282-021-01303-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "keywords": [
      "breast cancer patients", 
      "HR status", 
      "breast cancer", 
      "cancer patients", 
      "HER2 expression", 
      "HER2-low breast cancer", 
      "HER2-negative breast cancer", 
      "primary breast cancer patients", 
      "HER2-positive breast cancer", 
      "frequency of HER2", 
      "prognosis of HER2", 
      "Comparison of prognosis", 
      "HER2-negative patients", 
      "poor prognostic factor", 
      "early breast cancer", 
      "low HER2 expression", 
      "trastuzumab deruxtecan", 
      "clinical characteristics", 
      "prognostic factors", 
      "better prognosis", 
      "clinical trials", 
      "HER2 amplification", 
      "different prognosis", 
      "treatment strategies", 
      "patients", 
      "immunohistochemistry score", 
      "prognosis", 
      "cancer", 
      "HER2", 
      "overall frequency", 
      "significant differences", 
      "status", 
      "current study", 
      "group", 
      "IHC1", 
      "IHC2", 
      "expression", 
      "therapy", 
      "MethodsWe", 
      "subtypes", 
      "trials", 
      "scores", 
      "frequency", 
      "factors", 
      "differences", 
      "study", 
      "Institute", 
      "amplification", 
      "data", 
      "strategies", 
      "biological data", 
      "comparison", 
      "characteristics", 
      "interest", 
      "destiny"
    ], 
    "name": "The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status", 
    "pagination": "234-241", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1141720951"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-021-01303-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34622383"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-021-01303-3", 
      "https://app.dimensions.ai/details/publication/pub.1141720951"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_886.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12282-021-01303-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01303-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01303-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01303-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-021-01303-3'


 

This table displays all metadata directly associated to this object as RDF triples.

251 TRIPLES      22 PREDICATES      93 URIs      81 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-021-01303-3 schema:about N042bdc4a9a5e46428f0dceac5c2878fa
2 N330004f5cc214cb0b2645679f5a22137
3 N3961854f04204932824c4bc70fad5daf
4 N7f2feaa89ea44c728e3d256f6bf40ca8
5 N8d68da750642435e85214aae9c46a885
6 Na91b0d0868d54c5aa8dc51fc6dd17946
7 Nc9981b48cfbc43fb91a24c1d4254e93f
8 Ncc89678506f94390a2986b5251772b6d
9 anzsrc-for:11
10 anzsrc-for:1112
11 schema:author N74f22f273c6e4ba89896cd92c4591b16
12 schema:citation sg:pub.10.1007/s00428-016-1940-y
13 sg:pub.10.1007/s10549-015-3407-2
14 sg:pub.10.1007/s10549-019-05148-5
15 sg:pub.10.1038/s41523-020-00208-2
16 schema:datePublished 2021-10-07
17 schema:datePublishedReg 2021-10-07
18 schema:description PurposeThe DESTINY-Breast04 clinical trial is currently investigating whether trastuzumab deruxtecan (T-DXd) is effective in HER2-low as well as HER2-positive breast cancer. This highlights the interest in treatment strategies for patients with HER2-low breast cancer. The current study was therefore designed to determine the frequency of HER2-low among all breast cancers, and to compare the prognosis of HER2-low patients with that of HER2-negative patients.MethodsWe retrospectively reviewed the biological data from 4,918 of 4,977 primary breast cancer patients who attended our institute. We quantified the overall frequency of breast cancer patients with a new HER2-low subtype that was defined by an immunohistochemistry score of IHC1 + or IHC2 + /ISH−. We then compared the clinical characteristics and prognosis of HER2-low patients with that of patients who did not have HER2 amplification (HER2-0).ResultsLow HER2 expression was found in 3169 (64.4%) patients; 2860 (58.1%) were HR-positive and 309 (6.3%) were HR-negative. Among HER2-0 patients, 681 (13.9%) were HR-positive and 157 (3.2%) were HR-negative. The HER2-0 group tended to have more poor prognostic factors than the HER2-low group, irrespective of HR status. There were no statistically significant differences between the prognosis of HER2-low and HER2-0 patients, regardless of HR status. However, patients in the HER2-low group tended to have better prognosis than those in the HER2-0 group.ConclusionHER2-low patients did not have a significantly different prognosis than HER2-0 patients, regardless of HR status. However, we should consider tailoring therapies for patients with HRE2-low early breast cancer according to their HR status.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree true
22 schema:isPartOf N659b645b24d74ff1857d458667df5165
23 N8c72ddcbcb9543589c91860d11846dc4
24 sg:journal.1021080
25 schema:keywords Comparison of prognosis
26 HER2
27 HER2 amplification
28 HER2 expression
29 HER2-low breast cancer
30 HER2-negative breast cancer
31 HER2-negative patients
32 HER2-positive breast cancer
33 HR status
34 IHC1
35 IHC2
36 Institute
37 MethodsWe
38 amplification
39 better prognosis
40 biological data
41 breast cancer
42 breast cancer patients
43 cancer
44 cancer patients
45 characteristics
46 clinical characteristics
47 clinical trials
48 comparison
49 current study
50 data
51 destiny
52 differences
53 different prognosis
54 early breast cancer
55 expression
56 factors
57 frequency
58 frequency of HER2
59 group
60 immunohistochemistry score
61 interest
62 low HER2 expression
63 overall frequency
64 patients
65 poor prognostic factor
66 primary breast cancer patients
67 prognosis
68 prognosis of HER2
69 prognostic factors
70 scores
71 significant differences
72 status
73 strategies
74 study
75 subtypes
76 therapy
77 trastuzumab deruxtecan
78 treatment strategies
79 trials
80 schema:name The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
81 schema:pagination 234-241
82 schema:productId N284b1532dce44ca9963361a6f62a3f53
83 N3272e3581b1c4597b0b690eaf9d46517
84 Nd16553ae969744a08c7948077cdb9cdb
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141720951
86 https://doi.org/10.1007/s12282-021-01303-3
87 schema:sdDatePublished 2022-05-20T07:38
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher Na4091665832f4401866485915521ca38
90 schema:url https://doi.org/10.1007/s12282-021-01303-3
91 sgo:license sg:explorer/license/
92 sgo:sdDataset articles
93 rdf:type schema:ScholarlyArticle
94 N042bdc4a9a5e46428f0dceac5c2878fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Receptor, ErbB-2
96 rdf:type schema:DefinedTerm
97 N284b1532dce44ca9963361a6f62a3f53 schema:name pubmed_id
98 schema:value 34622383
99 rdf:type schema:PropertyValue
100 N3233534216eb4339a00d8dc8b50d0914 rdf:first sg:person.011635171771.80
101 rdf:rest N91dd95c051bd4004aa45c143563af874
102 N3272e3581b1c4597b0b690eaf9d46517 schema:name dimensions_id
103 schema:value pub.1141720951
104 rdf:type schema:PropertyValue
105 N330004f5cc214cb0b2645679f5a22137 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Retrospective Studies
107 rdf:type schema:DefinedTerm
108 N3961854f04204932824c4bc70fad5daf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Female
110 rdf:type schema:DefinedTerm
111 N3b5099a51fe84fadbe06d6441770adf3 rdf:first sg:person.012167214007.81
112 rdf:rest N607fdbb16c0549469a8d76b1f3e756a5
113 N4e89acd5b6c24a05874a9f845a402cc8 rdf:first sg:person.01332406364.07
114 rdf:rest Nc05d464934c8446eb430701e6c016b3f
115 N5bdebf3813354d23a770ec39b2e6fd4c rdf:first sg:person.011661742244.56
116 rdf:rest Ne0652ab37b1a4d8d86894fe532c4bee2
117 N607fdbb16c0549469a8d76b1f3e756a5 rdf:first sg:person.015174445210.44
118 rdf:rest N3233534216eb4339a00d8dc8b50d0914
119 N659b645b24d74ff1857d458667df5165 schema:volumeNumber 29
120 rdf:type schema:PublicationVolume
121 N74f22f273c6e4ba89896cd92c4591b16 rdf:first sg:person.012576646500.12
122 rdf:rest Nd569e2b4dc034bedb9ef050256689f7f
123 N7f2feaa89ea44c728e3d256f6bf40ca8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Humans
125 rdf:type schema:DefinedTerm
126 N8c72ddcbcb9543589c91860d11846dc4 schema:issueNumber 2
127 rdf:type schema:PublicationIssue
128 N8d68da750642435e85214aae9c46a885 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Trastuzumab
130 rdf:type schema:DefinedTerm
131 N91dd95c051bd4004aa45c143563af874 rdf:first sg:person.0643151743.73
132 rdf:rest Na15f06eceec145d8998deb8984657f2f
133 Na15f06eceec145d8998deb8984657f2f rdf:first sg:person.0711265143.20
134 rdf:rest Nc043c98dd1ef47dbbcd455486c72756b
135 Na4091665832f4401866485915521ca38 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 Na91b0d0868d54c5aa8dc51fc6dd17946 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Breast Neoplasms
139 rdf:type schema:DefinedTerm
140 Nb156040a849a42439a12fea0883cdcba rdf:first sg:person.012735232557.29
141 rdf:rest N5bdebf3813354d23a770ec39b2e6fd4c
142 Nc043c98dd1ef47dbbcd455486c72756b rdf:first sg:person.01030570677.84
143 rdf:rest N4e89acd5b6c24a05874a9f845a402cc8
144 Nc05d464934c8446eb430701e6c016b3f rdf:first sg:person.013142720612.73
145 rdf:rest rdf:nil
146 Nc9981b48cfbc43fb91a24c1d4254e93f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Immunohistochemistry
148 rdf:type schema:DefinedTerm
149 Ncc89678506f94390a2986b5251772b6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prognosis
151 rdf:type schema:DefinedTerm
152 Nd16553ae969744a08c7948077cdb9cdb schema:name doi
153 schema:value 10.1007/s12282-021-01303-3
154 rdf:type schema:PropertyValue
155 Nd569e2b4dc034bedb9ef050256689f7f rdf:first sg:person.0757400343.31
156 rdf:rest Nb156040a849a42439a12fea0883cdcba
157 Ne0652ab37b1a4d8d86894fe532c4bee2 rdf:first sg:person.014731505151.04
158 rdf:rest N3b5099a51fe84fadbe06d6441770adf3
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
163 schema:name Oncology and Carcinogenesis
164 rdf:type schema:DefinedTerm
165 sg:journal.1021080 schema:issn 1340-6868
166 1880-4233
167 schema:name Breast Cancer
168 schema:publisher Springer Nature
169 rdf:type schema:Periodical
170 sg:person.01030570677.84 schema:affiliation grid-institutes:grid.410800.d
171 schema:familyName Hattori
172 schema:givenName Masaya
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030570677.84
174 rdf:type schema:Person
175 sg:person.011635171771.80 schema:affiliation grid-institutes:grid.410800.d
176 schema:familyName Kataoka
177 schema:givenName Ayumi
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011635171771.80
179 rdf:type schema:Person
180 sg:person.011661742244.56 schema:affiliation grid-institutes:grid.410800.d
181 schema:familyName Nozawa
182 schema:givenName Kazuki
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011661742244.56
184 rdf:type schema:Person
185 sg:person.012167214007.81 schema:affiliation grid-institutes:grid.410800.d
186 schema:familyName Ozaki
187 schema:givenName Yuri
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012167214007.81
189 rdf:type schema:Person
190 sg:person.012576646500.12 schema:affiliation grid-institutes:grid.410800.d
191 schema:familyName Horisawa
192 schema:givenName Nanae
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012576646500.12
194 rdf:type schema:Person
195 sg:person.012735232557.29 schema:affiliation grid-institutes:grid.410800.d
196 schema:familyName Takatsuka
197 schema:givenName Daiki
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012735232557.29
199 rdf:type schema:Person
200 sg:person.013142720612.73 schema:affiliation grid-institutes:grid.410800.d
201 schema:familyName Iwata
202 schema:givenName Hiroji
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013142720612.73
204 rdf:type schema:Person
205 sg:person.01332406364.07 schema:affiliation grid-institutes:grid.410800.d
206 schema:familyName Sawaki
207 schema:givenName Masataka
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332406364.07
209 rdf:type schema:Person
210 sg:person.014731505151.04 schema:affiliation grid-institutes:grid.410800.d
211 schema:familyName Endo
212 schema:givenName Yuka
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014731505151.04
214 rdf:type schema:Person
215 sg:person.015174445210.44 schema:affiliation grid-institutes:grid.410800.d
216 schema:familyName Sugino
217 schema:givenName Kayoko
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015174445210.44
219 rdf:type schema:Person
220 sg:person.0643151743.73 schema:affiliation grid-institutes:grid.410800.d
221 schema:familyName Kotani
222 schema:givenName Haruru
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643151743.73
224 rdf:type schema:Person
225 sg:person.0711265143.20 schema:affiliation grid-institutes:grid.410800.d
226 schema:familyName Yoshimura
227 schema:givenName Akiyo
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711265143.20
229 rdf:type schema:Person
230 sg:person.0757400343.31 schema:affiliation grid-institutes:grid.410800.d
231 schema:familyName Adachi
232 schema:givenName Yayoi
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757400343.31
234 rdf:type schema:Person
235 sg:pub.10.1007/s00428-016-1940-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1005592412
236 https://doi.org/10.1007/s00428-016-1940-y
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/s10549-015-3407-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009019478
239 https://doi.org/10.1007/s10549-015-3407-2
240 rdf:type schema:CreativeWork
241 sg:pub.10.1007/s10549-019-05148-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111893543
242 https://doi.org/10.1007/s10549-019-05148-5
243 rdf:type schema:CreativeWork
244 sg:pub.10.1038/s41523-020-00208-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134289053
245 https://doi.org/10.1038/s41523-020-00208-2
246 rdf:type schema:CreativeWork
247 grid-institutes:grid.410800.d schema:alternateName Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan
248 Department of Clinical Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan
249 schema:name Department of Breast Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan
250 Department of Clinical Oncology, Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, 464-8681, Nagoya-City, Aichi, Japan
251 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...